Thrombogenicity

Tcelna is a personalized T-cell immunotherapy used in the treatment of Multiple Sclerosis. It is developed by Opexa Therapeutics, a company specializing in the development of personalized immunotherapies.

Overview

Tcelna is a novel T-cell immunotherapy that is personalized to each patient's disease profile. Tcelna is manufactured using Immune Response Guided Amplification (IRGA) technology. This process amplifies the T-cells that are reactive against the antigens believed to be important in the pathogenesis of Multiple Sclerosis.

Mechanism of Action

Tcelna works by reducing the number of circulating T-cells that react against myelin, a substance that insulates nerve fibers in the brain and spinal cord. These myelin-reactive T-cells are believed to be a key factor in the development of Multiple Sclerosis.

Clinical Trials

Tcelna has been evaluated in two Phase II clinical trials in patients with Relapsing Remitting Multiple Sclerosis (RRMS) and Secondary Progressive Multiple Sclerosis (SPMS). The results of these trials have shown that Tcelna may reduce brain volume loss, a key predictor of disability progression in MS patients.

Side Effects

The most common side effects of Tcelna are injection site reactions, flu-like symptoms, and fatigue. These side effects are generally mild to moderate in severity and are manageable with standard medical intervention.

Future Development

Opexa Therapeutics is currently evaluating Tcelna in a Phase IIb clinical trial in patients with SPMS. The results of this trial are expected to provide further evidence of Tcelna's potential as a treatment for Multiple Sclerosis.

Thrombogenicity Resources
Latest articles Most recent articles Ongoing trials	Wikipedia